https://scholars.lib.ntu.edu.tw/handle/123456789/591868
標題: | Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients | 作者: | MENG-KUN TSAI CHIH-YUAN LEE REY-HENG HU PO-HUANG LEE |
公開日期: | 2007 | 出版社: | Scientific Communications International Ltd | 卷: | 106 | 期: | 5 | 起(迄)頁: | 372-379 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose: Information is needed on renal function improvement after late elimination of calcineurin inhibitors (CNIs) and conversion to combined therapy of sirolimus (SRL) and mycophenolate mofetil (MMF) in Asian renal transplant recipients. Methods: A single-arm prospective study was undertaken to assess the outcome of stable Taiwanese renal transplant recipients who had CNI withdrawn and received combined SRL and MMF therapy. The primary endpoints were acute rejection and renal function. The secondary endpoints were graft and patient survival, side effects and infectious complications. Therapeutic drug monitoring of SRL and MMF was conducted during the study period. Results: Thirty patients were recruited at 9-72 (31.7 ± 18.6) months post-transplantation. The graft and patient survival rates were both 100% at 12 months, though one of the 30 patients (3.33%, 1/30) had biopsyproven acute rejection. On paired t test, the estimated glomerular filtration rates (GFR) from 4 to 12 months were significantly higher than the baseline GFR. The average trough level of SRL was 7.38 ± 3.74 ng/mL at 12 months and the average abbreviated area under the concentration curve of mycophenolic acid was 64.86 ± 36.62 mg/L. hour at an average MMF dose of 1.56 ± 0.45 g/day. However, two patients (6.67%, 2/30) had tuberculosis (TB) reactivation at 3 and 4 months, respectively, after the combined SRL and MMF therapy. Conclusion: Conversion to combined SRL and MMF therapy improved renal function in stable renal transplant recipients, though the risk of TB reactivation should be kept in mind when the combined therapy is employed in the Asian countries with a high prevalence of TB. ? 2007 Elsevier & Formosan Medical Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-34250666209&doi=10.1016%2fS0929-6646%2809%2960322-3&partnerID=40&md5=3d0c2f449802e094713aebe0654d0f9b https://scholars.lib.ntu.edu.tw/handle/123456789/591868 |
ISSN: | 0929-6646 | DOI: | 10.1016/S0929-6646(09)60322-3 | SDG/關鍵字: | calcineurin inhibitor; cyclosporin A; ethambutol; isoniazid; moxifloxacin; mycophenolic acid 2 morpholinoethyl ester; pyrazinamide; rapamycin; rifampicin; steroid; streptomycin; tacrolimus; acute graft rejection; adult; aged; area under the curve; article; Asian; clinical article; controlled study; drug blood level; drug dose reduction; drug monitoring; drug substitution; drug withdrawal; female; glomerulus filtration rate; graft recipient; graft survival; human; infectious complication; kidney biopsy; kidney function; kidney transplantation; male; outcome assessment; postoperative period; prevalence; prospective study; Student t test; survival rate; Taiwan; tuberculosis |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。